241 related articles for article (PubMed ID: 34782428)
1. Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial.
Hua Y; You R; Wang Z; Huang P; Lin M; Ouyang Y; Xie Y; Zou X; Liu Y; Duan C; Liu Y; Gu C; Liu R; Yang Q; Jiang R; Zhang M; Ding X; Chen S; Lin C; Sun R; Chen M
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782428
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
You R; Liu YP; Huang PY; Zou X; Sun R; He YX; Wu YS; Shen GP; Zhang HD; Duan CY; Tan SH; Cao JY; Li JB; Xie YL; Zhang YN; Wang ZQ; Yang Q; Lin M; Jiang R; Zhang MX; Hua YJ; Tang LQ; Zhuang AH; Chen QY; Guo L; Mo HY; Chen Y; Mai HQ; Ling L; Liu Q; Chua MLK; Chen MY
JAMA Oncol; 2020 Sep; 6(9):1345-1352. PubMed ID: 32701129
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Liu YP; Wen YH; Tang J; Wei Y; You R; Zhu XL; Li J; Chen L; Ling L; Zhang N; Zou X; Hua YJ; Chen YM; Chen L; Lu LX; Chen MY; Wen WP
Lancet Oncol; 2021 Mar; 22(3):381-390. PubMed ID: 33600761
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
You R; Zou X; Ding X; Zhang WJ; Zhang MX; Wang X; Xu HS; Liu YL; Ouyang YF; Duan CY; Gu CM; Wang ZQ; Liu YP; Hua YJ; Huang PY; Chen MY
Med; 2022 Oct; 3(10):664-681.e6. PubMed ID: 36041429
[TBL] [Abstract][Full Text] [Related]
6. Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial.
Cao X; Huang HY; Liang CX; Lin ZC; Zhou JY; Chen X; Huang YY; Zhan ZJ; Ke LR; Han LJ; Xia WX; Tang LQ; Guo SS; Liang H; Guo X; Lv X
Nat Commun; 2024 Jan; 15(1):949. PubMed ID: 38297016
[TBL] [Abstract][Full Text] [Related]
7. 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma.
Chen L; Zhang Y; Lai SZ; Li WF; Hu WH; Sun R; Liu LZ; Zhang F; Peng H; Du XJ; Lin AH; Sun Y; Ma J
Oncologist; 2019 Jan; 24(1):e38-e45. PubMed ID: 30082487
[TBL] [Abstract][Full Text] [Related]
8. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
[TBL] [Abstract][Full Text] [Related]
10. Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
Niu X; Hu C; Kong L
J Cancer Res Clin Oncol; 2013 Jun; 139(6):1063-71. PubMed ID: 23525586
[TBL] [Abstract][Full Text] [Related]
11. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Wang Z; Ying J; Xu J; Yuan P; Duan J; Bai H; Guo C; Li L; Yang Z; Wan R; Fei K; Zhao Z; Du X; Zhao J; Lv N; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2013770. PubMed ID: 33017026
[TBL] [Abstract][Full Text] [Related]
12. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.
Yang J; Dong L; Yang S; Han X; Han Y; Jiang S; Yao J; Zhang Z; Zhang S; Liu P; Qin Y; Wu H; Feng H; Yao S; Sun Y; Song H; Shi Y
Eur J Cancer; 2020 May; 130():182-192. PubMed ID: 32224416
[TBL] [Abstract][Full Text] [Related]
13. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results.
Hu J; Bao C; Gao J; Guan X; Hu W; Yang J; Hu C; Kong L; Lu JJ
Cancer; 2018 Jun; 124(11):2427-2437. PubMed ID: 29579324
[TBL] [Abstract][Full Text] [Related]
14. A Multicentre UK Study of Outcomes of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy ± Chemotherapy.
Slevin F; Pan S; Mistry H; Sen M; Foran B; Slevin N; Dixon L; Thomson D; Prestwich R
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):238-249. PubMed ID: 31813661
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
16. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
[TBL] [Abstract][Full Text] [Related]
17. IMRT improves local control in patients with nasopharyngeal carcinoma compared with conventional radiotherapy: propensity score-matched analysis.
Ma Z; Umezawa R; Yamamoto T; Ishikawa Y; Takahashi N; Takeda K; Suzuki Y; Tang L; Ito K; Kadoya N; Jingu K
Jpn J Clin Oncol; 2021 Aug; 51(9):1444-1451. PubMed ID: 34250545
[TBL] [Abstract][Full Text] [Related]
18. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
19. Effect of total dose and fraction size on survival of patients with locally recurrent nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a phase 2, single-center, randomized controlled trial.
Tian YM; Zhao C; Guo Y; Huang Y; Huang SM; Deng XW; Lin CG; Lu TX; Han F
Cancer; 2014 Nov; 120(22):3502-9. PubMed ID: 25056602
[TBL] [Abstract][Full Text] [Related]
20. Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma.
Xu H; Li W; Zhang H; Wang H; Hu L; Gu Y; Wang D
BMC Cancer; 2023 Dec; 23(1):1259. PubMed ID: 38129782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]